ERBB2 and non-small cell lung carcinoma: Among 1688 advanced NSCLC patients without EGFR gene mutations according to prior testing, the following driver alterations were detected: 17.0% for KRAS mutations; 8.4% for EGFR mutations; 6.3% for ERBB2 mutations; 4.2% for BRAF mutations; 4% for ROS1 fusion; 3% for RET fusion; 3% for ALK fusion; 2% for MET exon 14‐skipping mutation; and 1% for the KRAS mutations and BRAF mutations combined (total rate, 48.9%).13